Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC September 30, 2025
TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer September 30, 2025
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in TNBC September 30, 2025
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811) September 26, 2025
Avenzo Therapeutics Announces $60 Million Series B Financing to support pipeline advancement of oncology drug candidates September 23, 2025
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant September 23, 2025
Pidnarulex (CX-5461) + Cemiplimab (Libtayo®) combo to be tested in Ph 1/2 clinical trial for MSS CRC patients September 23, 2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer September 23, 2025
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti September 23, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked ADC September 23, 2025
Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer September 16, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
Radiance Biopharma signs Exclusive License Agreement with Novatim Immune Therapeutics for RB-601™ (KY-0301), the c-MET/EGFR-targeting ADC September 10, 2025
Silexion Therapeutics Announces Selection of CRO to Support Upcoming Ph 2/3 Clinical Trials for SIL204 September 10, 2025
CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value September 9, 2025
TREOS Bio, Charité Berlin, and Junshi Biosciences to Launch Pivotal Ph 2 Trial of PolyPEPI1018, toripalimab, and SoC combo in Refractory MSS CRC September 3, 2025
CHARM Therapeutics raises $80M in Series B financing to advance development of menin inhibitor for AML September 3, 2025
Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US September 3, 2025
